Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3862995B in Healthy Participants and Participants With COPD
NCT06154837Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of gsk3862995b in chronic obstructive pulmonary disease (COPD) (9 arms), sponsored by GSK. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events up to 48 weeks, Number of Participants with Clinically significant changes in laboratory values up to 42 weeks and 2 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
gsk3862995b
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06154837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154837.